Loading
A phase 1/2 trial of ATX-295 run by Accent Therapeutics, now recruiting.
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer is a phase 1/2 interventional study registered as NCT06799065 by Accent Therapeutics, with 218 participants planned, started 2025-03-21. Conditions recorded: Advanced Solid Tumors, Breast Cancer Recurrent, Ovarian Cancer, High-grade Serous Ovarian Carcinoma, Triple Negative Breast Cancer, sqNSCLC and Squamous Non-small-cell Lung Cancer. Interventions recorded: ATX-295 and ATX-295 and bevacizumab (or biosimilar).
Shares Accent Therapeutics, Breast cancer (all types), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Accent Therapeutics, Breast cancer (all types), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Ovarian cancer, Triple-negative breast cancer (TNBC), Non-small-cell lung cancer and the tag pipeline.
Shares Ovarian cancer, Triple-negative breast cancer (TNBC), Non-small-cell lung cancer and the tag pipeline.
Shares Ovarian cancer, Triple-negative breast cancer (TNBC), Metastatic cancer (cancer that has spread), Non-small-cell lung cancer and the tag pipeline.
Shares Breast cancer (all types), Triple-negative breast cancer (TNBC), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Ovarian cancer, Breast cancer (all types), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Triple-negative breast cancer (TNBC), Metastatic cancer (cancer that has spread), Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/